

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/562,085	
				Filing Date		December 23, 2005	
				First Named Inventor		Bernard Verrier	
				Group Art Unit		Unassigned	
Examiner Name		Unassigned					
Attorney Docket Number		033339/305755					
Sheet	1	of	1				
U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		
/T.P.T./	1	US-4,897,426	01-30-1990	Llinas et al.			
/T.P.T./	2	US-6,359,015 B1	03-19-2002	Charness et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached	
/T.P.T./	3	WO 02/062327 A2	08-15-2002	Likhodi et al.			
OTHER DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached	
/T.P.T./	4	Gribkoff et al., "The Substituted Benzimidazolone NS004 Is an Opener of the Cystic Fibrosis Chloride Channel," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 15, Issue of April 15, 1994, pp. 10983-10986.					
	5	Copy of the International Search Report for PCT/FR2004/001662, completed December 1, 2004. no publication date					
Examiner Signature		/Timothy Thomas/		Date Considered	08/08/2007		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.